ArticleFrontiers in immunology2021
Description and Analysis of a Novel Subtype of the Anti-Synthetase Syndrome Characterized by Frequent Attacks of Fever and Systemic Inflammation in a Single-Center Cohort Study.
Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 16 citations in OpenAlex.
- Clinical characteristics, organ damage and survival in idiopathic inflammatory myopathies: a long-term retrospective cohort study.Rheumatology international · 2026Article
- Evaluating the value of superoxide dismutase in anti-synthetase syndrome associated with interstitial lung disease.Clinical rheumatology · 2026Article
- Risk Factors for Recurrence of the Anti-Synthetase Syndrome Related Interstitial Lung Disease.Immunity, inflammation and disease · 2026Article
- Clinical profiles associated with rapidly progressive interstitial lung disease in antisynthetase syndrome: A multicentric cohort study (TYPASS study).Journal of internal medicine · 2026Article
- Combination of tofacitinib and tacrolimus therapy in refractory interstitial lung disease associated with anti-synthetase syndrome: a case series of six patients.Frontiers in immunology · 2026Article
- CNS demyelination risk in biologic-treated rheumatic disease: are we capturing the full picture?Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Article
- Myocarditis in anti-synthetase syndrome: clinical features and diagnostic modalities.Rheumatology (Oxford, England) · 2024Article
- [A unicenter real-world study of the correlation factors for complete clinical response in idiopathic inflammatory myopathies].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2024Article
- Anti-synthetase syndrome in a child with pneumomediastinum: a case report and literature review.BMC pulmonary medicine · 2024Review
- Fever in the initial stage of IIM patients: an early clinical warning sign for AE-ILD.Advances in rheumatology (London, England) · 2023Article
- A multidisciplinary approach to the diagnosis of antisynthetase syndrome.Frontiers in medicine · 2022Review
- Tocilizumab Treatment in a Patient of Refractory Anti-EJ Positive ASyS: A Case Report.Journal of investigative medicine high impact case reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The aim of this study was to investigate anti-synthetase syndrome (ASyS) patients who presented with recurrent episodes of fever and systemic inflammation. Methods: A retrospective cohort of Chinese ASyS patients (n=126) in our center (between January 2013 and January 2020) was included. Patients presenting with concomitant autoimmune rheumatic diseases or malignancies were subsequently excluded. The number of non-infectious fever attacks and attack frequency were recorded and calculated. Patients with two or more attacks and within the upper three quartiles of attack frequency were defined as high-inflammation group. Univariate and multivariate analyses were carried out to characterize the high-inflammation subtype. Results: Out of 113 eligible patients with an average of 5 years follow up, 25 patients were defined as the high-inflammation group (16 for anti-Jo1, 9 for anti-PL7), with an average of 1.12 attack/patient-year. Compared to low-inflammation group (0-1 attack only and a frequency lower than 0.5 attack/patient-year), the high-inflammation group had higher occurrence of fever and rapid progressive interstitial lung disease (RPILD) as the first presentation (84% Conclusions: ASyS with recurrent systemic inflammatory episodes reflects a subtype of more aggressive and refractory disease in the spectrum of ASyS. Increased awareness of this subtype might lead to more appropriate management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.